Preimplantation Genetic Diagnosis (PGD) is presented as a very early form of diagnosis based on new Assisted Reproduction techniques, making genetic study of embryos possible before being transferred to the mother’s uterus.
Preimplantation genetic diagnosis is suitable for couples where one or both partners are carriers of monogenic diseases:
This genetic study also offers carriers of structural (Translocations, Inversions, etc.), and numerical (mosaics for Klinefleter syndrome, etc.) chromosomal anomalies.
Undertaking a subsequent prenatal diagnosis is always recommended due to the high rate of mosaicism present in the embryos.
In conclusion, the genetic analysis of human embryos during the IVF cycle (PGD) is the combination of advances in embryology and molecular genetics. The results allow the identification of genetic anomalies at the embryonic level in stages prior to implantation, preventing the transfer of affected embryos.
The PGD technique can select chromosomically normal embryos before their transfer to the uterus.
Today, preimplantation genetic diagnosis has become a powerful tool for improvement of the effectiveness of in vitro fertilisation programmes.
1. Biopsy of blastomeres.
After an in vitro fertilisation process and through micromanipulation techniques, 1 or 2 blastomeres are extracted from the embryo which are normally on a third day in a stage of 6-8 cells. The embryonic biopsy is carried out in an inverted microscope with a micromanipulation system similar to that used for the ICSI technique. With a holding pipette, the embryo is held, and with an aspirating pipette a hole is made in the pellucid zone, immediately proceeding to aspirate 1 or 2 blastomeres on which appropriate analysis will be carried out. The elimination of these cells from the embryo does not affect its viability or capacity for survival, as the remaining cells are still totipotent and capable of forming a complete, perfectly normal individual.
2. Genetic studies.
A) Study of aneuploidies and structural alterations if the condition we wish to locate is due to a numerical or structural anomaly of the chromosomes (chromosomal translocations or inversions). To do so, the FISH (Fluorescent In Situ Hybridisation) technique is used, which only studies a few chromosomes, or CGH arrays (microarray-based comparative genomic hybridisation) which expands the study to all chromosomes. Today, massive sequencing techniques are being used, offering genetic analysis of all DNA. It is a more powerful, faster, more precise technique.
FISH allows dyeing of the centromeric area or specific regions of different chromosomes with various coloured fluorochromes. It is used today to simultaneously identify chromosomes 16, 22,13, 18, 21 and sexual chromosomes X and Y.
Full study of 24 chromosomes (CGH array). Through the use of new genetic analysis technologies, we have tools (arrays) which provide us with all genetic information of the embryo, numerical and/or structural alterations. A detailed sequencing of each chromosome of each embryo is carried out, allowing alterations to be detected in minute regions which may lead to genetic disorders.
CGH arrays consist of an analysis of the whole DNA of the patient, of all their chromosomes, comparing this with that of a healthy control sample. It allows the study of all chromosomes in their full scope. It is more precise than FISH in the detection of aneuploidies and structural alterations.
Through a comprehensive chromosomal screening (CCS), massive sequencing techniques of DNA allow the study of almost all DNA of the 46 chromosomes which make up our karyotype. It gives us precise information on the genetic health of the embryo and is more precise than arrays with CGH.
The study of aneuploidies or structural chromosomal alterations is mainly intended for:
One of the main applications of all these techniques of molecular biology within in vitro fertilisation is the determination of the sex of embryos. Currently, a combination of PCR and FISH techniques offer us practically 99% reliability in determining the sex of preimplantation embryos. In Spain, it is only possible to select the sex with these techniques when there is a high likelihood of transmission of a serious genetic disorder related with sex.
B) Study of Monogenic Diseases if the condition we wish to locate is due to one or several mutations and we wish to know whether the embryo is a carrier of any of these, the PCR (polymerase chain reaction) technique is used, which will allow us to amplify the DNA of the embryo and detect the presence or absence of the genetic mutation we are investigating in its genome.
PCR consists of analysing the mutation of the gene responsible for a hereditary condition in one or two cells obtained after the biopsy of the embryo. On the third day of the embryo’s development, when it has 6-8 cells, a hole is made from which one cell is extracted, on which the genetic study will be carried out.
After the embryo analysis process, and once we have checked and selected the healthy embryos, the embryo transfer is carried out as in a conventional IVF treatment. The results obtained with these techniques are similar to those obtained with classic IVF.
You choose the transfer date, and we will organize your trip and the treatment cycle, adapting everything to your personal needs.
We have many years of experience with patients from abroad and in particular from Italy, so we know just what you need to make you feel at home. With our help, you can undergo the treatment in two simple steps:
1º Make a first visit to FIV Valencia, during which you can also vitrify a sperm sample. That way you can come the second time just for the IVF transfer!
2º Choose the day that best suits your needs to make the transfer! We will take care of the rest.
Over 90% of our patients become pregnant. Pregnancy rate over 50% per attempt.
The most advanced technologies
20 years of experience and successes
C/ Santa Rosa, 12; 46021
VALENCIA (España)